Galectin Therapeutics (GALT) Cash & Equivalents (2010 - 2026)

Galectin Therapeutics has reported Cash & Equivalents for 17 years, with the latest figure at $14.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 89.75% year-over-year to $14.1 million; the trailing twelve-month figure through Mar 2026 stood at $14.1 million (up 89.75% YoY), and the FY2025 full-year result was $17.7 million, up 17.2% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $14.1 million, down from $17.7 million in the prior quarter.
• The five-year high for Cash & Equivalents was $31.6 million in Q1 2022, with the low at $7.4 million in Q1 2025.
• Average Cash & Equivalents over 5 years is $19.3 million, with a median of $18.0 million recorded in 2023.
• Year-over-year, Cash & Equivalents plunged 68.45% in 2025 and surged 89.75% in 2026.
• Tracing GALT's Cash & Equivalents over 5 years: stood at $18.6 million in 2022, then jumped by 38.02% to $25.7 million in 2023, then slumped by 41.08% to $15.1 million in 2024, then gained by 17.2% to $17.7 million in 2025, then retreated by 20.43% to $14.1 million in 2026.
• The last three Cash & Equivalents figures came in at $14.1 million (Q1 2026), $17.7 million (Q4 2025), and $11.5 million (Q3 2025), per Business Quant data.

Peer Comparison